Grupo Medico Camino Sc

Mexico City, Mexico City 3310

0 studies enrolling now · 11 studies all time

What they study most

Arthritis, Psoriatic, Atopic Dermatitis, Breast Cancer, Breast Neoplasms, Crohn's Disease, Follicular Lymphoma, Neoplasm Metastasis, Nonalcoholic Steatohepatitis, Psoriatic Arthritis

Studies at this site

• A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer — Running, not enrolling
• Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer — Running, not enrolling
• A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer — Running, not enrolling
• A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer — Running, not enrolling
• A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer — Stopped early
• A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH) — Completed
• A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease — Completed
• A Study of LY3375880 in Adults With Moderate-to-Severe Atopic Dermatitis — Stopped early
• Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis — Completed
• A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06) — Completed
• Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors — Completed